US2020261371A1PendingUtilityA1
Osmotic drug delivery system
Assignee: SUPERNUS PHARMACEUTICALS INCPriority: Apr 27, 2006Filed: Feb 20, 2020Published: Aug 20, 2020
Est. expiryApr 27, 2026(expired)· nominal 20-yr term from priority
A61K 31/5575A61K 9/28A61K 9/20A61K 9/0004A61K 9/2013A61P 9/04A61K 31/5585A61K 9/1623A61K 31/557A61K 9/2077A61P 9/12A61P 7/02A61K 9/1652A61P 29/00A61P 9/00A61P 27/02A61K 9/286A61P 43/00A61K 9/282A61K 9/2826A61P 9/10A61P 11/00A61P 35/00A61P 7/04A61K 31/192
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Claims
exact text as granted — not AI-modified1 .- 18 . (canceled)
19 . A method of treating pulmonary hypertension in a human subject in need thereof, comprising orally administering to the human subject a sustained release formulation effective to produce a treprostinil plasma concentration above around 200 pg/ml for a period of up to about 12 hours, wherein the sustained release formulation is an osmotic controlled tablet comprising treprostinil or a salt thereof in an amount of 1.0 to 5.0 mg based on weight of treprostinil.
20 . The method of claim 19 , wherein the osmotic controlled tablet comprises treprostinil diethanolamine.
21 . The method of claim 20 , wherein the osmotic controlled tablet comprises a release enhancing agent.
22 . The method of claim 21 , wherein the release enhancing agent is sodium lauryl sulfate.
23 . The method of claim 19 , wherein the administration is performed at least twice per day.Join the waitlist — get patent alerts
Track US2020261371A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.